Kornimate/medical-research-clean huggingface dataset:
test and treat covid 65plus+

Conditions: SARS-CoV 2; COVID-19

Summary: patients over equal or older than 65 yearswill be treated with a hydroxychloroquine versus placebo reduced loading dose of 600mg on the first day followed with 400mg/day divided in 2x200mg for 6 more days resulting in a total duration of therapy of 7 days. measurement of hydroxychloroquine-levels will be performed on day 7, . a follow-up by video or telephone conference will be performed to observe drug intake and collect adverse events during treatment phase on a daily base on working days and once during the weekend (i.e. 6 out of 7 days). after treatment phase follow-up by telephone calls will be done on day 10, 30, 60 (+/- 2 days).


Eligibility criteria:
inclusion criteria: * written informed consent * age ≥ 65 years * mild to moderate symptomatic respiratory tract infection defined as not requiring hospital admission: spo2 \>94%, respiratory rate \<20, mental state alert, no signs of septic shock * proven sars-cov2 infection by throat swab (pcr) * onset of symptoms within the last 3 days before randomization * must be able to adhere to the study visit schedule and other protocol requirements in the investigator's opinion. i.e. must be able to answer to questions concerning symptoms and side effects and must be able to consent to the informed consent. exclusion criteria: * hospitalization at study inclusion * weight \<50 kg * acute myocardial infarction * severe heart failure, characterized as nyha class 3 or 4 * use of concomitant medications that prolong the qt/qtc interval. * qtc \>450ms * bilirubin ≥ 1,5 x unl, (except for known m. meulengracht) * ast/alt ≥ 3 x uln * albumine ≤ 2.8 g/dl * hemoglobin ≤ 9 g/dl * leucocytes ≤ 2000/µl * neutrophiles ≤ 1000/µl * thrombocytes ≤ 100.000/µl * troponin elevation * bnp \> 500 pg/ml * creatine kinase \> 5 x uln * creatinine \>1,5 mg/dl * uncorrected hypopotassemia or hypomagnesemia * history of hypoglycemic events * history of or present cardial arrhythmia (except atrial fibrillation or paroxysmal supraventricular tachycardia) * bradycardia \< 60 beats/min * history of retinopathy or maculopathy * psoriasis * myasthenia gravis * epilepsy * immunodeficiency syndromes or need for highly immunosuppressive medication * pre-existing medication with hydroxychloroquine * known g6pd deficiency. * participation in another interventional study * known hypersensibility to hydroxychloroquine and its derivates
mglide-care: a partnership with caregivers

Conditions: HTN

Summary: hypertension (htn) is the most significant stroke, cardiovascular disease and dementia risk factor and is substantially under-treated especially in older persons. in this study the investigators will develop mglide-care to address uncontrolled htn in people with mild cognitive impairment (mci) and early stage alzheimer's disease and alzheimer's disease related dementia (ad/adrd). mglide-care is adapted from mglide which is a mhealth (mobile health technology) mediated care model for htn care. aim 1 will engage stakeholders to study the acceptability of mhealth mediated htn care and will use their input to develop mglide-care. stakeholders are persons with early stage ad/adrd and mci, unpaid family caregivers, primary care providers, geriatricians and clinical pharmacists. aim 2 is a feasibility pilot to test mglide-care vs. usual care in 75 participants with uncontrolled htn and early stage ad/adrd or mci. caregivers will assist participants. outcomes will include htn control and participant and caregiver reported measures.


Eligibility criteria:
inclusion criteria: must meet all criteria * diagnosed with early stage ad/adrd or mci * have uncontrolled hypertension (htn) * have an unpaid, family caregiver * have established medical diagnosis of hypertension (htn) * english speaking * participant or caregiver must have a smartphone or mobile device (e.g. ipad) that can transmit blood pressure (bp) from the bp monitor * participant and caregiver capable and willing to comply with the entire study protocol * able to give voluntary written informed consent. exclusion criteria: any of the following will be an exclusion. * severe comorbid illness including end-stage kidney disease, end-stage liver disease, and life expectancy \<1 year, or if medical complexity of the patient precludes clinical trial participation * active illicit drug use (e.g. cocaine, methamphetamines, opioids, phencyclidine) since this will interfere with htn management * participant and caregiver unable to complete study tasks, including are homeless, will leave the country, or will relocate in the next 12 months * serious psychiatric illness that could interfere with treatment, assessment, or compliance including significant delusional disorders such as schizophrenia and bipolar illness * unable or unwilling to give consent.
efficacy and safety of exenatide once weekly suspension in subjects with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: to compare the effect on glycemic control (hba1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus. to examine the long-term (52 weeks of treatment) safety and effect on glucose control of exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * at least 18 years old * diagnosed with type 2 diabetes mellitus * hba1c 7.1 to 11%, inclusive, at screening * fasting plasma glucose \<280 mg/dl (15.5 mmol/l) * body mass index (bmi) \<=45 kg/m2, inclusive, at screening * treated with diet and exercise or a stable regimen of metformin, sulfonylurea, pioglitazone or any 2 of these agents exclusion criteria: * history of pancreatitis or triglycerides \>=500 mg/dl * medullary carcinoma or multiple endocrine neoplasia (men2) or a family history of either * active cardiovascular disease * presence of congestive heart failure * liver disease * history of severe gastrointestinal diseases * repeated severe hypoglycemia within the last 6 months * any previous use of exenatide or other glucagon-like peptide-1 (glp-1 ) analog * dipeptidyl peptidase-4 (dpp-4) inhibitor use in the last 3 months
diamondtemp global registry

Conditions: Arrhythmia

Summary: the diamondtemp™ global registry is a prospective, global, multi-center, observational post-market registry.

the diamondtemp™ global registry is a prospective, global, multi-center, observational post-market registry. the purpose of this clinical study is to describe clinical performance and safety data in a broad patient population treated with the commercially available diamondtemp™ family of cardiac ablation catheters (hereafter referred to as the diamondtemp™ ablation system) and followed according to the standard of care at each respective institution. the follow up period is intended to align with standard practice and subjects will be followed for a minimum of 12 months post-procedure.

Eligibility criteria:
inclusion criteria: * subject is ≥ 18 years of age or minimum age as required by local regulations * planned procedure using commercially available diamondtemp™ ablation system * willing to comply with study requirements and give ic (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements exclusion criteria: * subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager * subject with exclusion criteria required by local law
recovery of individuals with alcohol use disorders based on roy adaptation model

Conditions: Addiction, Alcohol

Summary: abstract aim: this study aimed to determine the effect of individualized nursing interventions based on the roy adaptation model on the recovery of alcohol addicts. method: this was an experimental study with pretest-posttest, follow-up, and a control group. it included 64 individuals who completed their detoxification process and met the inclusion criteria. the experimental group was provided with individualized care, and interventions were made in line with the roy adaptation model. the personal behaviors that could be related to recurrence (physiological, self-concept, role function, and mutual commitment) and the stimuli that caused recurrence (focal and affecting) were assessed, objectives were determined, and nursing interventions were carried out in line with these objectives. the interventions planned for diagnosing ineffective coping were selected according to the patients' needs among the "support coping" interventions under the title of the behavioral area in the nursing intervention classification (nic). the data were collected using an introductory information form, the recovery assessment scale (ras), the turkish version of the world health organization quality of life instrument (whoqol-bref-tr), and the penn alcohol craving scale (pacs).


Eligibility criteria:
inclusion criteria: diagnosed with alcohol use disorder according to dsm 5 completed the detoxification phase were able to understand the scales and forms and maintain individual interviews were between 30 and 60 years of age exclusion criteria: * with a psychotic disorder

Keywords: recovery alcohol use disorder roy adapation model nursing intervention
clinical study to evaluate the bio-psychosocial impact of mobile app for diabetes type 1 ("social diabetes")

Conditions: Diabetes Mellitus, Type 1

Summary: based on international recommendations, the current clinical research project considers the effectiveness of a free diabetes app with a ce (conformité européenne) mark, "social diabetes", which incorporates the addition of a glucometer ("glucomen areo") it allows using nfc technology the automatic introduction of data, evaluating the impact on metabolic results and other related psychosocial variables, in people with diabetes 1 through a randomized randomized study during 6 months of follow-up.

randomized study in people with type 1 diabetes in intensive insulin therapy mdi with analogues and with hba1c\> 7% to the usual clinical follow-up options (cg) vs use of social diabetes app (gi) for 6 months. the current clinical research project considers the effectiveness of a free diabetes app with a ce mark, "social diabetes", which incorporates the addition of a glucometer ("glucomen areo") it allows using nfc (near field communication) technology the automatic introduction of data, evaluating the impact on metabolic results and other related psychosocial variables, in people with diabetes 1. the substitution of the usual face-to-face medical visit every 3-4 months by the incorporation of an app system has a similar effect in terms of glycemic control (measured through hba1c) in patients with dm1 treated with multiple doses of insulin per day (mdi). ) and inadequate metabolic control (hba1c\> 7%). in addition, it could save costs and consumption of health resources, and improve both the quality of life and the satisfaction of people with dm1. the present study will be carried out under the usual conditions of clinical practice. no pharmacological intervention, other than the usual clinical practice, will be applied to the included patients. the people with diabetes 1 included in the study have a profile of "expert patient" having completed their diabetological education program at basic and advanced level (count of rations, calculations of ratios and sensitivity indexes) in such a way that the application will only be an aid in your daily decision making (mathematical calculations of ratios, is, and recommended insulin doses, which you usually have to do "by hand").

Eligibility criteria:
inclusion criteria: * patients with dm1 over 1 year evolution. * age ≥18 and \<65 years. * hba1c prior to the inclusion of the study\> 7%. * intensive insulin treatment with mdi in basal-bolus regimen. * patients with basic digital skills and with 3g mobile phone and nfc technology. * patients who have given their informed consent in writing. exclusion criteria: * treatment with subcutaneous insulin infusor (isci) * chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism correctly treated and controlled). * pregnancy or pregnancy planning. * diabetes mellitus type 2. * severe psychological alterations. * absence of collaboration (informed consent). * patients who are participating in other clinical studies.

Keywords: mobile app
liquid biopsy to enable diagnostics and monitoring for immune-mediated lymphoproliferative disorders

Conditions: Lymphoproliferative Disorders; Lymphoproliferative Disorder Following Transplantation

Summary: immune-mediated lymphoproliferative disorders (ild), as per world health organization (who haem 5) classification, are rare conditions associated with a poor outcome. current management of ild is focusing on prevention (e.g.) early detection of ild with preemptive epstein barr virus (ebv) deoxyribonucleic acid (dna) levels monitoring, however, this approach is useless for the early detection of ebv-negative ild. therapeutic management consists of a reduction in immunosuppressive therapy (ris), allowing mostly partial and transient responses. rituximab, an anti-cd20 (cluster differentiation 20) antibody, provides roughly 20-25% of complete and durable responses, thus the majority of ild patients will require immunochemotherapy, burden with significant toxicity in this challenging population. implementation of liquid biopsy, also called circulating tumor dna (ctdna) in plasma or serum is an area of investigation that is becoming increasingly relevant for clinical practice, allowing for non-invasive monitoring of disease status. early detection and monitoring of ild using ctdna may allow for preemptive therapy, improved risk-stratification and ultimately, lead to outcome improvement. this multicenter swiss project will allow a better understanding of ild mutational landscape and pathogenesis, which could lead to the development of new screening and monitoring approaches for patients suffering from ild.

in this observational prospective study, the investigators will collect clinical data from subjects' charts through a dedicated multicenter electronic case report form (ecrf). whenever available, pet-ct will be transferred through a web-based imaging and diagnosis exchange network (widen) to perform a blinded independent review of staging and response. biological samples included 20 ml of blood collected at each of the following planned clinical points in time: i) at ild diagnosis, ii) after first cycle of therapy, iii) at interim response assessment, iv) at the end-of-treatment, v) at 3 months follow-up, vi) at 12 months follow-up, vii) at disease progression, if applicable. additional samples could be collected if clinically relevant. additionally, the investigators will request formalin-fixed and paraffin-embedded tissue (ffpet) or fresh-frozen (ff) tissue slices/blocks at ild diagnosis from pathology departments of participating centers for retrospective ild subjects.

Eligibility criteria:
inclusion criteria: * any patient with a diagnosis of ild defined by the world health organization (who haem 5)(e.g. post-transplant setting, x-link, concomitant auto-immune disorders) exclusion criteria: * lymphoproliferative disorders non immune-mediated * lymphoproliferative disorders occurring in the context of a concomitant human immunodeficiency virus (hiv) infection

Keywords: immune-related lymphoproliferative disorders
the greek acute dance injuries registry

Conditions: Emergencies

Summary: dance is a highly demanded physical activity with a high rate of acute and emergent events (aee). no systematic prospective study has been conducted in any greek population of dance students for the registration of the aee and their possible predisposing factors. this is a prospective cohort study, the purpose of which is to register the aee risk factors, their long-term follow-up, and the potential aee during an academic year in adult dance students in athens, greece.

dance, as a physical activity, is considered as one of the most demanding activities at a young age with a high rate of acute and emergent events (aee). although dancers perform movement combinations that require high athletic ability, often their physical fitness levels appear to be unexpectedly low and the majority of them will experience at least one injury a year. determination of the aee predisposing factors in dancers is necessary to reduce their percentage rates, and until now no systematic prospective study has been conducted in a greek population of vocational dance schools' students to register both the aee themselves and their possible predisposing factors. the primary objective of the study is to register the risk factors for the aee occurrence in students at higher vocational schools of dance in athens and their long-term follow-up. secondary objectives are to register potential aee during an academic year and to investigate possible correlations of the above parameters, both among themselves and with socio-demographic, anthropometric, psychometric and medical characteristics of the sample. finally, a translation and cross-cultural adaptation to a greek population of the dance functional outcome survey (dfos) scale will be carried out. this is a prospective cohort study with the study population being adult students of 8 higher vocational schools of dance in athens. a registration of socio-demographic, anthropometric and medical characteristics, as well as an electrocardiogram, will be carried out at the beginning of the academic year. core stabilization, balance, body composition, aerobic capacity, dance motor control, dance functional ability, quality of life, fatigue, depressive symptoms, anxiety, stress, performance satisfaction, risk for developing eating disorders, athletic burnout, and predisposition to psychological flow will be registered at the beginning and at the end of the academic year.

Eligibility criteria:
inclusion criteria: * undergraduate student in one of the eight higher vocational dance schools of the study * age ≥18 years * ability to understand, write and speak greek * written consent for participating into the study exclusion criteria: * student listener who is not officially participating to the whole educational program * pregnancy * deny to participate and/or give a written consent for participating into the study

Keywords: dance emergent events predisposing risk factors dance medicine
evaluation of valaciclovir in patients with chickenpox

Conditions: Varicella

Summary: this study will assess the safety and efficacy, and the pharmacokinetics of aciclovir and valaciclovir in children with chickenpox following oral administration of valaciclovir, for the purpose of seeking approval of valaciclovir hcl for the treatment of chickenpox.


Eligibility criteria:
inclusion criteria: * subjects aged 1 year to less than 12 years with a clinical diagnosis of chickenpox within 48 hours of the onset of the rash. exclusion criteria: * history of hypersensitivity reactions. * impaired hepatic or renal function. * gastrointestinal dysfunction. * serious underlying disease. * weigh over 40kg. * vaccinated for chickenpox.

Keywords: chicken pox varicella vzv pharmacokinetics
family empowerment for enhanced development

Conditions: Obesity, Childhood; Feeding Behavior

Summary: this study evaluates the feasibility and preliminary effects of offering the mealtime prep intervention to low-income families with young children. all enrolled families will receive the mealtime prep intervention in the home to evaluate the effects on child nutrition.

children have not been spared from the obesity epidemic. there is a great need for innovative interventions to help families build healthy habits early in life for obesity prevention. low-income preschoolers have a disproportionately high rate of childhood obesity, and their families face complex barriers to healthy behavior change. this proposed pilot study will examine the feasibility of delivering the promoting routines of exploration and play during mealtime (mealtime prep) intervention in a sample of low-income families with young children (ages 2-5). our parent-mediated intervention is designed to promote healthy dietary variety using routine family meals, positive reinforcement, social modeling, and food exploration and play. by harnessing the behavior change capacity of behavioral activation to alter daily mealtimes incrementally, parents are empowered to overcome barriers to healthy habit formation. each family will participate in a six-week intervention that is delivered by occupational therapy clinicians in the home environment. each session will last approximately one hour and include individualized parent-training and a parent-led mealtime with direct feedback from the clinician. we planned to screen up to 100 potential parent and child participants, with a plan to deliver intervention to 20 child participants.

Eligibility criteria:
inclusion criteria: child: * within age range 2-5 years * reside in a low-income household (as specified by income within the range to qualify for special supplemental nutrition program for women, infants, and children. parent: * \>18 years old * ability to read and speak in english * willing to participate in 6 home-based intervention sessions exclusion criteria: * none

Keywords: early childhood, family, occupational therapy
prevalence of small bowel polyps in patients with sporadic duodenal adenomas

Conditions: Polyps

Summary: little is known about the prevalence of small bowel polyps in patients with sporadic duodenal/ampullary polyps. the investigators aim to investigate the prevalence of small bowel polyps in patients with sporadic (ie not related to fap or pjs) duodenal/ampullary adenomas by performing small bowel capsule endoscopy and comparing the results to those acquired from a control cohort undergoing vce for accepted indication at our centre.

investigation for suspected sb tumors is an acceptable indication for vce. sb polyps occur frequently in patients with fap/pjs and in patients with fap, they are significantly more common in patients with duodenal/ampullary polyps. little is known about the prevalence of small bowel polyps in patients with sporadic duodenal/ampullary polyps. the primary hypothesis is that patients with sporadic (ie not related to fap or pjs) duodenal/ampullary adenomas have a higher prevalence of small bowel polyps compared with patients undergoing vce for various indications who have not had a duodenal polyp diagnosed or removed. patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at westmead hospital will receive vce examination. control population will consist of age matched controls having vce for ogib/ida at westmead hospital. patients will be required to have had a documented colonoscopy within the previous three years. if colonoscopy was not performed within this time frame, the patient will have a colonoscopy as part of the study protocol.

Eligibility criteria:
inclusion criteria: * cases - patients who were diagnosed with or underwent resection of a duodenal adenoma/ampulloma at westmead hospital between the years 2005-2014. * controls - patients undergoing vce procedure for the evaluation of obscure gastrointestinal bleeding (ogib) or iron deficiency anemia (ida). exclusion criteria: * none

Keywords: duodenal ampulla